TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.

TS-063433 — A new pharmacologic modality for treating AFib.

TS-063091 — A gene therapy approach to address the specific needs of failing hearts.

TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types

TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.

TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.

TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration

TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…

TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…

TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…

TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…

TS-062571 — The Need Coral reefs are declining at an alarming rate. When temperatures increase by as little as 1-2 °C above their normal thermal maximum for as little as ten days, corals become stressed, lose their endosymbiotic algae, and turn white – hence the term bleaching. When bleached, corals…

TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.

TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.

TS-062439 — The Need: Addressing the Growing Threat of Gram-Negative Bacterial Infections Gram-negative bacterial pathogens, including Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, are responsible for more than 35% of common hospital-acquired infections. These no…

TS-062421 — The Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million pe…

TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.

TS-062355 — The Need: In today's fast-paced and demanding world, the need for innovative solutions that enhance mental well-being and cognitive performance has never been greater. Recent scientific discoveries have highlighted the crucial role of the gut-brain connection in influencing human behavior and …

TS-062261 — The Need: Addressing the Zika Virus Outbreak The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…

TS-062232 — The Need The current demand in the market is for a safe and effective SARS-CoV-2 vaccine that can induce both antibody and T cell responses. The traditional understanding of antibody-based immunity is incomplete, as virus-infected cells are eliminated with the help of T cells. To combat SARS-CoV-2 …

TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…

TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…

TS-062097 — Novel polypeptides and polynucleotides targeting RyR2 to address dysregulated Ca2+ release.

TS-062096 — Using tissue nano-transfection to regulate BAT and increase 12,13-diHOME production to treat obesity, cardiovascular disease and type 2 diabetes.

TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.

TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.